Bank of America has removed its rating on Clorox CLX after the company's board rejected Carl Icahn's offer of $76.50/share, stating that the proposal was “neither credible nor adequate,” and noting that that staying the course [of] its existing plan is the best course of action for shareholders.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
